Research programme: PPAR agonists - Karo Pharma
Latest Information Update: 21 Dec 2016
At a glance
- Originator Karo Bio
- Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 12 Nov 2004 Discontinued - Preclinical for Type-2 diabetes mellitus in Sweden (unspecified route)
- 29 Jul 2003 Preclinical trials in Type-2 diabetes mellitus in Sweden (unspecified route)